首页 > 抗体蛋白 > 抗体
Purified anti-human IFN-γ Antibody
产品名称:
Purified anti-human IFN-γ Antibody
产品类别:
抗体
产品编号:
502501
产品应用:
502501
[价格]
规格 价格 库存
50µg ¥ 996 1

产品详情

Product Details

Verified Reactivity
Human
Reported Reactivity
Chimpanzee, Baboon, Cynomolgus, Rhesus
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Partially purified, native human IFN-γ
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

ELISA - Quality tested
WB - Verified
ICFC - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by ELISA assay. For ELISA Capture applications, the antibody should be titrated between 0.25 - 2 ?g/ml to determine optimal condition.?For Western blotting, the suggested use of this reagent is 0.5 - 2.0 ?g per ml. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

ELISA or ELISPOT Detection5: The biotinylated 4S.B3 antibody is useful as a detection antibody for a sandwich ELISA or ELISPOT assay, when used in conjunction with purified NIB42 antibody (Cat. No. 502402/502404) or purified MD-1 antibody (Cat. No. 507502/507513) as the capture antibody.
Flow Cytometry3,4,6-8: The fluorochrome-labeled 4S.B3 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-γ?-producing cells within mixed cell populations.
Additional reported applications (for the relevant formats) include: neutralization1,2, Western blotting, immunohistochemical staining of paraformaldehyde-fixed, saponin-treated tissue sections, and immunocytochemistry. The 4S.B3 antibody can neutralize the bioactivity of natural or recombinant IFN-γ.
Note: For testing human IFN-γ?in serum or plasma, BioLegend's ELISA Max? Sets (Cat. No. 430101 to 430106) are specially developed and recommended.

Application References

(PubMed link indicates BioLegend citation)
  1. Meager A, et al. 1984. J. Interferon Res. 4:619. (Neut)
  2. Meager A, 1987. Lymphokines and Interferons:A Practical Approach. IRL Press Ltd, Oxford, p. 105. (Neut)
  3. Sester M, et al. 2002. J. Virol. 76:3748. (ICFC)
  4. Infante-Duarte C, et al. 2000 J. Immunol. 165:6107. (ICFC)
  5. Goodier M, et al. 2000. J. Immunol. 165:139. (ELISA)
  6. Chen H, et al. 2005. J. Immunol. 175:591. (ICFC)
  7. Smeltz RB, 2007. J. Immunol. 178:4786. (ICFC)
  8. Iwamoto S, et al. 2007. J. Immunol. 179:1449. (ICFC) PubMed
  9. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (ICFC)
Product Citations
  1. Olson BM, et al. 2017. Cancer Immunol Res. 5:1074. PubMed
  2. Alroqi F, et al. 2017. J Clin Immunol. . 10.1007/s10875-017-0451-1. PubMed
  3. Wang W, et al. 2018. Cancer Cell. 34:757. PubMed
  4. Stras SF, et al. 2020. Developmental Cell. 51(3):357-373.e5.. PubMed
  5. Matthias J, et al. 2020. J Clin Invest. 130:4587. PubMed
  6. Willing A, et al. 2018. J Immunol. 200:974. PubMed
  7. Bobardt M, et al. 2020. PLoS One. 15:e0227715. PubMed
  8. Peeters MJW, et al. 2021. Front Immunol. 12:718863. PubMed
  9. Jilg N, et al. 2020. J Infect Dis. 222:1837. PubMed
  10. Cribbs AP, et al. 2021. Front Immunol. 12:626255. PubMed
  11. Aravena O, et al. 2017. Arthritis Res Ther. 19:8. PubMed
  12. Rodriguez-Salazar CA, et al. 2022. Viruses. 14:. PubMed
  13. Salerno F, et al. 2019. J Immunol. 202:714. PubMed
  14. Li H, et al. 2020. Front Immunol. 11:1777. PubMed
  15. Kameda M, et al. 2020. PLoS One. 15:e0241719. PubMed
  16. Martins MA, et al. 2017. AIDS Res Hum Retroviruses. 33:843. PubMed
  17. Park JB, et al. 2019. Mol Cells. 42:597. PubMed
  18. Walk J, et al. 2020. Front Immunol. 2.405555556. PubMed
  19. Bruno TC, et al. 2017. Cancer Immunol Res. 0.831944444. PubMed
  20. Martins M, et al. 2017. PLoS Pathog. 10.1371/journal.ppat.1006529. PubMed
  21. Macmillan ML, et al. 2021. Blood Adv. 5:1425. PubMed
  22. Singh AK, et al. 2017. Front Immunol. 0.513888889. PubMed
  23. Chang ZL, et al. 2018. Nat Chem Biol. 0.803472222. PubMed
  24. Sordo-Bahamonde C, et al. 2021. Cancers (Basel). 13:. PubMed
  25. Anna F, et al. 2021. J Immunother Cancer. 9:. PubMed
  26. Pompura SL, et al. 2021. J Clin Invest. 131:. PubMed
  27. Iwamoto S, et al. 2007. J Immunol. 179:1449. PubMed
  28. Stensland ZC, et al. 2022. iScience. 25:103626. PubMed
  29. Hwang HJ, et al. 2021. Immun Inflamm Dis. 9:274. PubMed
  30. Mou W, et al. 2017. BMC Immunol. 18:36. PubMed
RRID
AB_315226 (BioLegend Cat. No. 502501) AB_315227 (BioLegend Cat. No. 502502)

Antigen Details

Structure
Cytokine; dimer; 20-25 kD (Mammalian)
Bioactivity
Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APC
Cell Sources
CD8+ and CD4+ T cells, NK cells
Cell Targets
T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors
IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type
Tregs
Biology Area
Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family
Cytokines/Chemokines
Antigen References

1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press, San Diego.
2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321.
3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571.
4. Gray P, et al. 1987. Lymphokines 13:151.

Regulation
Upregulated by IL-2, FGF-basic, EGF; downregulated by vitamin D3 or DMN; labile at pH2
Gene ID
3458 View all products for this Gene ID
UniProt
View information about IFN-gamma on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线